NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Intrexon Corporation (NYSE:XON) resulting from allegations that Intrexon may have issued materially misleading business information to the investing public.
On April 21, 2016, Spotlight Research published a report on Intrexon asserting, among other things, that: (1) Intrexon’s technology has recently been questioned by high-ranking officials from the WHO, CDC and NIH; (2) Intrexon overstated revenues by 50% through transactions with related parties; (3) Intrexon’s technology platform is an overhyped, undifferentiated collection of commodity and failed products; and (4) Intrexon is the Theranos of the public markets. On this news, shares of Intrexon fell $9.73 per share or over 26% to close at $27.10 per share on April 21, 2016.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Intrexon investors. If you purchased shares of Intrexon on or before April 20, 2016, please visit the firm’s website at http://www.rosenlegal.com/cases-882.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.